Agenda for Day 3 - Wednesday 11 November, 2026Wednesday, 11 November 2026

The Asia-Pacific region is rapidly emerging as a transformative force in global biopharma, evolving from a manufacturing hub and clinical trial destination into a powerhouse of innovation, investment, and commercial opportunity. This session explores how APAC is reshaping the industry landscape through homegrown biotech innovation, increasing R&D capabilities, and growing capital markets that are attracting global attention. The discussion examines key trends driving the region's ascent, including regulatory modernization, cross-border partnerships, and the rise of China, Japan, South Korea, Singapore, and Australia as innovation centres while addressing the strategic considerations for Western companies seeking to access APAC markets and technologies. As deal flow between APAC and the rest of the world accelerates, the session provides insights into partnership models, investment opportunities, and the geopolitical and commercial factors that will define the region's role in shaping the future of global biopharma.